sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks Enmd-2076

Enmd-2076

CAS No.:
934353-76-1
Catalog Number:
AG00GU36
Molecular Formula:
C21H25N7
Molecular Weight:
375.4701
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥98%
1 week
United States
$112
- +
5mg
99%
1 week
United States
$223
- +
10mg
99%
1 week
United States
$307
- +
50mg
99%
1 week
United States
$807
- +
100mg
99%
1 week
United States
$1140
- +
Product Description
Catalog Number:
AG00GU36
Chemical Name:
Enmd-2076
CAS Number:
934353-76-1
Molecular Formula:
C21H25N7
Molecular Weight:
375.4701
MDL Number:
MFCD16619371
IUPAC Name:
6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine
InChI:
InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+
InChI Key:
BLQYVHBZHAISJM-CMDGGOBGSA-N
SMILES:
CN1CCN(CC1)c1nc(/C=C/c2ccccc2)nc(c1)Nc1n[nH]c(c1)C
UNII:
J6U9WP10T7
Properties
Complexity:
499  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
1  
Exact Mass:
375.217g/mol
Formal Charge:
0
Heavy Atom Count:
28  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
375.48g/mol
Monoisotopic Mass:
375.217g/mol
Rotatable Bond Count:
5  
Topological Polar Surface Area:
73A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.7  
Literature
Title Journal
ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Molecular cancer therapeutics 20110101
Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. British journal of haematology 20100801
3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective Aurora A kinase inhibitors. Bioorganic & medicinal chemistry letters 20100801
Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clinical cancer research : an official journal of the American Association for Cancer Research 20100601
Discovery and development of aurora kinase inhibitors as anticancer agents. Journal of medicinal chemistry 20090514
Properties